144 related articles for article (PubMed ID: 28508247)
1. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2017 Sep; 49(9):1691-1697. PubMed ID: 28508247
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Int Immunopharmacol; 2017 Sep; 50():48-54. PubMed ID: 28628770
[TBL] [Abstract][Full Text] [Related]
3. Uric acid increases cellular and humoral alloimmunity in primary human peripheral blood mononuclear cells.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Nephrology (Carlton); 2018 Jul; 23(7):610-615. PubMed ID: 28477373
[TBL] [Abstract][Full Text] [Related]
4. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of the aerobic glycolysis inhibitor dichloroacetate and of the Krebs cycle inhibitor LW6 on cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Liakopoulos V; Stefanidis I
Biomed Rep; 2017 Nov; 7(5):439-444. PubMed ID: 29181155
[TBL] [Abstract][Full Text] [Related]
6. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells.
Sounidaki M; Pissas G; Eleftheriadis T; Antoniadi G; Golfinopoulos S; Liakopoulos V; Stefanidis I
Biomed Rep; 2019 Jun; 1(1):1-5. PubMed ID: 31258898
[TBL] [Abstract][Full Text] [Related]
8. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Humoral Alloimmunity in Mixed Lymphocyte Reaction.
Pissas G; Eleftheriadis T
Bio Protoc; 2019 Jan; 9(2):e3139. PubMed ID: 33654885
[TBL] [Abstract][Full Text] [Related]
10. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors.
Mittal SK; Sharma RK; Gupta A; Naik S
Transplantation; 2009 Aug; 88(3):435-41. PubMed ID: 19667950
[TBL] [Abstract][Full Text] [Related]
11. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
Navarro-Villarán E; Tinoco J; Jiménez G; Pereira S; Wang J; Aliseda S; Rodríguez-Hernández MA; González R; Marín-Gómez LM; Gómez-Bravo MA; Padillo FJ; Álamo-Martínez JM; Muntané J
PLoS One; 2016; 11(8):e0160979. PubMed ID: 27518575
[TBL] [Abstract][Full Text] [Related]
12. Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy.
Granata S; Santoro G; Signorini L; Malerba G; Patuzzo C; Gambaro G; Stallone G; Zaza G
Eur J Pharmacol; 2019 Sep; 859():172494. PubMed ID: 31238062
[TBL] [Abstract][Full Text] [Related]
13. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
[TBL] [Abstract][Full Text] [Related]
14. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
Levitsky J; Gallon L; Miller J; Tambur AR; Leventhal J; Flaa C; Huang X; Sarraj B; Wang E; Mathew JM
Transplantation; 2011 Jan; 91(2):199-206. PubMed ID: 21239962
[TBL] [Abstract][Full Text] [Related]
15. Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation.
Tomita Y; Uehara S; Takiguchi S; Nakamura M
Transplant Proc; 2023 May; 55(4):792-796. PubMed ID: 37100735
[TBL] [Abstract][Full Text] [Related]
16. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
19. Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation.
Mathew JM; Kurian S; Cravedi P; Tambur A; Guo K; Zhao L; Levitsky J
Hum Immunol; 2021 Feb; 82(2):81-88. PubMed ID: 33213941
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
